Publications by authors named "Catherine C Li"
Article Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) is a serious illness where most patients live less than 3 years, but new treatments have been developed that help people live longer.!
- Researchers studied 3,637 Veterans with mCRPC to look at their age, race, and what treatments they received over two time periods, called Epoch 1 (2006-2010) and Epoch 2 (2011-2016).!
- They found that while older treatments like docetaxel were still used, newer treatments like abiraterone became more common, leading to longer survival times from 15 months in Epoch 1 to 23 months in Epoch 2.!
